Full text is available at the source.
Randomized, Placebo-Controlled Trial of Olanzapine as Maintenance Therapy in Patients With Bipolar I Disorder Responding to Acute Treatment With Olanzapine
Olanzapine as ongoing treatment in bipolar I patients who improve with initial olanzapine: a randomized placebo-controlled trial
AI simplified
Abstract
Patients receiving olanzapine experienced a median relapse time of 174 days, compared to 22 days for those on placebo.
- Olanzapine significantly increased the time to symptomatic relapse into any mood episode compared to placebo.
- The relapse rate for patients on olanzapine was lower at 46.7%, versus 80.1% for those on placebo.
- All types of mood episode relapses—manic, depressive, and mixed—occurred later in patients treated with olanzapine.
- Weight gain was the most common side effect associated with olanzapine, with patients gaining an average of 3.1 kg during the open-label phase.
- In the double-blind phase, patients on placebo lost a mean of 2.0 kg, while those on olanzapine gained an additional 1.0 kg.
AI simplified